NR4A1 and breast cancer: In a recent meta-analysis, it was found that the pooled cumulative incidence of BCBM was around 30% for the HER2-positive subgroup and the triple-negative subgroup, and 15% among patients with hormonal receptors positive HER2-negative breast cancer [6].